Spectrum Pharmaceuticals — Investor Day (March 2015)
132 slides from Spectrum Pharmaceuticals's investor day presentation, Mar 13, 2015
Slide 1: Spectrum Pharmaceuticals Analyst Day 2015
Exhibit 99.1 Spectrum Pharmaceuticals Analyst Day 2015
Slide 2: Safe Harbor Statement
Safe Harbor Statement This presentation contains forward-looking statements regarding future events and the future performance of Spectrum Pharmaceuticals that involve risks and uncertainties that could cause actual results to differ materially. These statements are based on management’s current bel
Slide 3: Analyst Day Agenda
Analyst Day Agenda Overall Business Strategy Dr. Raj Shrotriya Financial Review Kurt Gustafson Operational Highlights Joe Turgeon Research & KOL Presentations Dr. Lee Allen Commercial Perspective Tom Riga Questions & Answers Team
Slide 4: Introduction
Introduction Rajesh Shrotriya Chairman and CEO
Slide 5: Spectrum's Focus & Overview
Spectrum’s Focus & Overview AT SPECTRUM PHARMACEUTICALS “WE BRING OUR EXPERTISE AND PASSION FOR EXCELLENCE TO ACQUIRE, DEVELOP AND COMMERCIALIZE PHARMACEUTICALS FOR UNMET MEDICAL NEEDS WHILE BUILDING VALUE FOR OUR SHAREHOLDERS.”
Slide 6: Positioned For Long-Term Growth
Positioned For Long-Term Growth STRONG LONG-TERM GROWTH DRIVERS MULTIPLE ASSETS FUND Your text here Your text here Your text here Your text here Approved Drugs LATE-STAGE ASSETS WITH GROWTH POTENTIAL CE Melphalan Your text here Poziotinib Business Development and Lifecycle Management Your text here
Slide 7: Financial Review
Financial Review Kurt Gustafson Executive Vice President, Chief Financial Officer and Principal Accounting Officer
Slide 8: Non-GAAP Earnings in 2014
Non-GAAP Earnings in 2014 $25 30% Increase Year over Year $21.4 $20 $15 2014 Product $10 Sales: 2013 Product $187 $5 Sales: $144 Million Million $ 2013 2014 $(5) $(5.6) $(10) Non-GAAP Earnings (Loss) excludes stock-based compensation, depreciation, 8 intangibles amortization, taxes, shareholder liti
Slide 9: Breakeven cash flow in 2014 excluding Business Development
Breakeven cash flow in 2014 excluding Business Development $200 $180 $21 $160 $160 $35 $140 $13 $133 $120 $100 $80 $60 $40 $20 12/31/2013 Cash Non-GAAP Milestones Working Capital 12/31/2014 Cash Earnings $ millions
Slide 10: Operational Highlights
Operational Highlights Joseph Turgeon President and Chief Operating Officer
Slide 11: Key Recent Milestones
Key Recent Milestones 2Q 2014 3Q 2014 4Q 2014 1Q 2015 TODAY
Slide 12: Analyst Day Highlights
Analyst Day Highlights & SPECTRUM
Slide 13: Spectrum is Positioned For Long-Term Growth
Spectrum is Positioned For Long-Term Growth SPI-2012: Late-stage drug targeting blockbuster market CE Melphalan: Under FDA review PDUFA date: October 23, 2015 Apaziquone: Late-stage drug could satisfy unmet need in bladder cancer Poziotinib: A promising Phase 2 pan-HER inhibitor
Slide 14: Positioned For Long-Term Growth
Positioned For Long-Term Growth STRONG LONG-TERM GROWTH DRIVERS LATE-STAGE ASSETS WITH GROWTH POTENTIAL MULTIPLE ASSETS Your text here CE stage Melphalan Your text here Your text here assets Apaziquone Your text here Your text here Poziotinib Your text here Business Development and Lifecycle Managem
Slide 15: Research and KOL Presentations
Research and KOL Presentations Lee Allen, MD PhD Chief Medical Officer
Slide 16: Medical Development Group Driving Portfolio Advancement
Spectrum’s Medical Development Group Aggressively Driving Portfolio Advancement PROMISING FUTURE STRATEGIC DEVELOPMENT THE DELIVERING Multiple pipeline assets Experienced TEAM Proven track record of delivery
Slide 17: Spectrum's Pipeline
Spectrum’s Pipeline Zevalin (ibritumomab tiuxetan) 6020 targeted radioimmunotherapy (SPI-2012) (recombinant human 6CSF) Long-acting Granulocyte colony- stimulating factor analog
Slide 18: Experienced Team with Proven Track Record
Experienced Team with Proven Track Record CONTINUING TO DELIVER ON THE PROMISE… Poziotinib SPI-2012 Apaziquone CE-Melphalan
Slide 19: KOL Presentations
KOL Presentations SPI-2012 Novel biologic with blockbuster potential to mitigate neutropenia CE Melphalan Propylene glycol-free Melphalan with an improved stability profile for the treatment of Multiple Myeloma Apaziquone Next generation alkylating agent addressing an unmet medical need for the trea
Slide 20: SPI-2012
Spectrum Pharmaceuticals Analyst Day 2015 SPI-2012
Slide 21: Jeffrey L. Vacirca
Jeffrey L. Vacirca MD, FACP SPI-2012 CEO, Managing Partner & Chief of Clinical Research at North Shore Hematology/Oncology Associates Medical Director for ION/ASBSG Vice-President, Community Oncology Alliance CEO & President National Translational Research Group.
Slide 22: Our Involvement With SPI-2012 Phase Studies
Our Involvement With SPI-2012 Phase 2 Studies
Slide 23: SPI-2012 is a Novel Biologic Conjugated Form of Recombinant Human G-CSF Analogue
SPI-2012 is a Novel Biologic Chemically Conjugated Form of Recombinant Human G-CSF Analogue Non-glycosylated FC Region of IgG4 Antibody (low immunogenicity; prolonged half-life) LAPS-G-CSF® Long Acting Protein Discovery (LAPSCOVERY) Technology – Technology confers long-acting properties through decr
Slide 24: Phase 1: ANC Profiles of SPI-2012 and Pegfilgrastim
Phase 1: ANC Profiles of SPI-2012 and Pegfilgrastim (Healthy Volunteers) Absolute Neutrophil Count (ANC) SPI-2012—270 ìg/kg (4 mg as G-CSF) /L) 40 pegfilgrastim ?6mg (as G-CSF) 10 9 X 30 SPI-2012—135 ìg/kg (2 mg as G-CSF) (cells 20 ANC 0 2 4 6 8 10 12 14 16 18 20 22 Study Drug Time (day) SPI-2012 27
Slide 25: SPI-2012 Phase Study Summary
SPI-2012 Phase 2 Study Summary
Slide 26: SPI-2012 Phase Study Design
SPI-2012 Phase 2 Study Design Sample Size (N) Key Entry Criteria Doses Primary Objective Secondary Objectives N=144, n=36 per treatment arm of 45, 135, and 270 Newly diagnosed patients with histologically confirmed breast cancer who are candidates for adjuvant or neoadjuvant chemotherapy with doceta
Slide 27: SPI-2012 Demographic Characteristics
SPI-2012 Demographic Characteristics SPI-2012 SPI-2012 SPI-2012 Pegfilgrastim Total Parameter 45 µg/kg 135 µg/kg 270 µg/kg 6 mg(N=147) (N=39)(N=36)(N=36)(N=36) Age n39 36 36 36 147 Mean 59.8 56.8 55.7 60.4 58.2 SD 11.31 10.63 9.79 10.43 10.64 Median 62.0 59.0 56.5 60.5 59.0 Min, Max 33, 77 32, 74 38
Slide 28: SPI-2012 Duration of Severe Neutropenia Primary Endpoint
SPI-2012 Duration of Severe Neutropenia (DSN)- Cycle 1 Primary Endpoint SPI-2012 SPI-2012 SPI-2012 Pegfilgrastim µg/kg 135 µg/kg 270 µg/kg 6 mg (N=39)(N=36)(N=36)(N=36) DSN (Days) 0 25 (64%) 29 (81%) 35 (97%) 31 (86%) 1 (3%) 3 (8%) 1 (3%) 1 (3%) 5 (13%) 3 (8%) 0 (0%) 2 (6%) 5 (13%) 0 (0%) 0 (0%) 2 (
Slide 29: SPI-2012 Duration of Severe Neutropenia Primary Endpoint
SPI-2012 Duration of Severe Neutropenia (DSN)- Cycle 1 Primary Endpoint SPI-2012 SPI-2012 SPI-2012 Pegfilgrastim µg/kg 135 µg/kg 270 µg/kg 6 mg (N=39)(N=36)(N=36)(N=36) DSN (Days) n 39 36 36 36 Mean 1.03 0.44 0.03 0.31 SD 1.547 1.275 0.167 0.822 Difference with Pegfilgrastim 0.72 0.14 -0.28 N/A Non-
Slide 30: SPI-2012 Median ANC Over Time in Cycle 1
SPI-2012 Median Absolute Neutrophil Count (ANC) Over Time in Cycle 1 40 SPI-2012—270 ìg/kg SPI-2012—135 ìg/kg 35 pegfilgrastim—6 mg 30 SPI-2012—45 ìg/kg /L) 25 9 (10 ANC 20 15 0 5 10 15 20 Chemo Study Days Therapy Drug Similar ANC trends between 135 µg/kg arm and pegfilgrastim dosing arms ANC recove
Slide 31: SPI-2012 Percentage of Patients with No Severe Neutropenia in Cycle 1
SPI-2012 Percentage of Patients with No Severe Neutropenia in Cycle 1 No significant difference compared to pegfilgrastim Similar ANC trends between 135 µg/kg arm and pegfilgrastim dosing cohorts ANC recovery was considerably stronger in 270 µg/kg arm
Slide 32: SPI-2012 Summary of Selected Treatment-Related Adverse Events
SPI-2012 Summary of Selected Treatment-Related Adverse Events (? 5%) SPI-2012 SPI-2012 SPI-2012 Description Pegfilgrastim ug/kg 135 ug/kg 270 ug/kg Any AE 20 (51%) 19(51%) 23(64%) 21(58%) Bone Pain 8(21%) 8(22%) 9(25%) 10(28%) Myalgia 5(13%) 1(3%) 4 (11%) 7(19%) Arthralgia 5(13%) 5 (14%) 3(8%) 5(14%
Slide 33: SPI-2012 Pivotal Phase 3: ADVANCE Study Schema
SPI-2012 Pivotal Phase 3: ADVANCE Study Schema Two 500 Patient trials, one in North America one International Study Screening Treatment Period Four 21-day Cycles End of Cycle Visit Period Day 1 Day 2 SPI-2012 (3.6 mg, SC) 30*Chemotherapy 250 patients ?30 Days Days 500 patients After the end Pegfilgr
Slide 34: SPI-2012 Clinical Summary to Date
SPI-2012 Clinical Summary to Date Over 230 patients treated to date Innovative biologic based on elegant science Non-inferior efficacy to pegfilgrastim Comparable safety profile to pegfilgrastim Low immunogenicity Novel biologic expands patient options
Slide 35: Captisol-Enabled Melphalan
Captisol-Enabled™ Melphalan
Slide 36: Parameswaran Hari, MD
Parameswaran Hari, MD, MRCP, MS Captisol-Enabled™ Melphalan Armand J. Quick/William F. Stapp Professor of Hematology Medical College of Wisconsin Director of the Adult Blood and Marrow Transplant Program Section Head of Hematologic Malignancies and Transplantation Division of Hematology and Oncology
Slide 37: Annual Number of Transplant Recipients in the US by Transplant Type
Annual Number of Transplant Recipients in the US by Transplant Type Autologous Allogeneic 14000 12000 10000 8000 Transplants 6000 4000 2000 0 Pasquini MC, Zhu X. Current use and outcome of hematopoietic stem cell transplantation: CIBMTR Summary Slides, 2014. Available at: http://www.cibmtr.org
Slide 38: Indications for Hematopoietic Stem Cell Transplants in the US, 2012
Indications for Hematopoietic Stem Cell Transplants in the US, 2012 Allogeneic (Total N=7,554) Autologous (Total N=11,145) 7000 Melphalan based >95% 6000 Other melphalan based 5000 Transplants 4000 3000 of Number 1000 0 Myeloma/ AML ALL CML NHL HD MDS/MPD CLL Aplastic Other Other PCD Anemia Non-Mali
Slide 39: Unmet Needs with Current IV Melphalan Formulation
Unmet Needs with Current IV Melphalan Formulation Unmet needs with IV melphalan revolve around safety, dose reconstitution and dose administration Poor stability (<60 minutes) makes advanced planning and coordination necessary Poor solubility requires dilution into high volumes of saline Administrat
Slide 40: Captisol-Enabled Melphalan Formulation
Captisol-Enabled Melphalan Formulation + Captisol-Enabled DNA Melphalan Captisol Melphalan Crosslinking Addresses issues with solubility, stability, and tissue delivery – Standard Melphalan needs to be used within one hour of reconstitution; limits use for prolonged infusions Propylene glycol-free f
Slide 41: CE-Melphalan Phase 2a Pharmacokinetic Study Bioequivalence Design
CE-Melphalan Phase 2a Pharmacokinetic Study Bioequivalence Design A Phase 2a, Open-Label, Randomized, Pharmacokinetic Comparative, Cross-Over Study of Melphalan HCl for Injection and Standard Melphalan for Injection for Myeloablative Conditioning in Multiple Myeloma Patients Undergoing Autologous Tr
Slide 42: CE-Melphalan Phase 2a Efficacy Overview
CE-Melphalan Phase 2a Pharmacokinetic Study Efficacy Overview All patients (100%) achieved myeloablation and engraftment – Median time to myeloablation was 3 days – Median time to neutrophil engraftment was 11 days Time and Rate of Total Time and Rate of Total Myeloablation(N=24) Engraftment(N=24) E
Slide 43: CE-Melphalan Phase 2a Melphalan Plasma Concentration
CE-Melphalan Phase 2a Pharmacokinetic Study Melphalan Plasma Concentration Bioequivalence demonstrated – i.e., the lower and upper 90% CI within the FDA established limits of 80% to 125% Cmax: 112% AUC 0-t: 110% AUC-inf: 110% Successful myeloablation (Day +3) Successful engraftment (Day +11) No addi
Slide 44: CE-Melphalan Phase 2a Safety Overview
CE-Melphalan Phase 2a Pharmacokinetic Study Safety Overview Adverse event safety profile in this study appears consistent with what has been reported with high-dose treatment with standard Melphalan – No patients discontinued prematurely TEAEs ?50% of Patients Nausea 100% Diarrhea 96% Vomiting 88% H
Slide 45: CE-Melphalan Phase 2a Pharmacokinetic Study Summary
CE-Melphalan Phase 2a Pharmacokinetic Study Summary Results from the Phase 2a study (N=24): CE-Melphalan is bioequivalent to standard Melphalan – CE-Melphalan (propylene glycol-free) peak and systemic exposure were slightly greater than with standard Melphalan The efficacy and safety profile were co
Slide 46: CE-Melphalan Phase 2b Study Design and Assessments
CE-Melphalan Phase 2b Safety and Efficacy Study Design and Assessments Multicenter, Open-label study of high-dose CE-Melphalan (propylene glycol-free) conditioning in MM pts undergoing ASCT – (Relapsed MM patients were also eligible) Pretreatment Followup Study Period Period Period Daily safety MM r
Slide 47: CE-Melphalan Phase 2b Endpoint Analyses
CE-Melphalan Phase 2b Safety and Efficacy Study Endpoint Analyses Primary Endpoint Treatment-related mortality- 0% Secondary Endpoints Summary of Myeloablation Rate, Neutrophil Engraftment Rate, and Platelet Engraftment Rate Following CE-Melphalan (Propylene Glycol-Free) Administration (Safety Popul
Slide 48: CE-Melphalan Phase 2b Efficacy – Myeloma Response
CE-Melphalan Phase 2b Safety and Efficacy Study Efficacy – Myeloma Response Summary of Multiple Myeloma Responses at Day 100 Following CE-Melphalan (Propylene Glycol-Free) Administration (Response-Evaluable Population) Response Assessment Total N (%) All Stages of Disease 61 Overall Response Rate 58
Slide 49: CE-Melphalan Phase 2b Safety: AEs
CE-Melphalan Phase 2b Safety and Efficacy Study Safety: AEs Summary of Adverse Events (>25% by Preferred Term) (N=61) System Organ Class All AEs Grade 3 Grade 4 Preferred Term N (%) N (%) N (%) Patients with Adverse Events of Any Causality 60(98%) 57(93%) 50(82%) Gastrointestinal Disorders 58(95%) 6
Slide 50: CE-Melphalan Phase 2b Safety: Mucositis
CE-Melphalan Phase 2b Safety and Efficacy Study Safety: Mucositis Summary of Mucositis Assessment Following CE-Melphalan (Propylene Glycol-Free) Administration (Safety Population) Baseline Day -2 Day 0 Day 7 Day 14 Grade(Mel Tmt)(ASCT) N (%) N (%) N (%) N (%) N (%) Grade 0 55(98%) 51(94%) 49(88%) 27
Slide 51: CE-Melphalan Phase 2b Summary
CE-Melphalan Phase 2b Safety and Efficacy Study Summary CE-Melphalan (propylene glycol-free) high dose therapy: – Myeloablation followed by engraftment established in all 61 patients – Neutrophil engraftment achieved in all 61 patients; median time—12 days – Platelet engraftment achieved in all 61 p
Slide 52: Apaziquone
Spectrum Pharmaceuticals Analyst Day 2015 Apaziquone
Slide 53: Bladder Cancer and Apaziquone
Bladder Cancer and Apaziquone Spectrum Investors Day Friday March 13, 2015 Prof Dr. Fred Witjes Dept Urology RadboudUMC, Nijmegen
Slide 54: Epidemiology versus Awareness
Epidemiology versus Awareness
Slide 55: Prostate cancer
Prostate cancer 58 Radboudumc
Slide 56: Testicular cancer
Testicular cancer Over zijn gevecht tegen iad en het van de Tour IT’S NOT ABOUT THE BIKE 56 Radboudumc
Slide 57: Bladder cancer
Bladder cancer Radboudumc
Slide 58: Cancer incidence (= new cases/year)
Cancer incidence (= new cases/year) Tumour Incidence US Incidence EU Bladder ca 68,810 149,000 Colon ca 145,290 376,400 Lung ca 172,570 381,500 Prostate ca 232,090 237,800 Breast ca 211,240 370,100
Slide 59: Prevalence (= all cases being treated)
Prevalence (= all cases being treated) Tumour Incidence US Incidence EU Bladder ca 68,810 149,000 Prevalence estimate >600,000 >1,100,000 Colon ca 145,290 376,400 Lung ca 172,570 381,500 Prostate ca 232,090 237,800 Breast ca 211,240 370,100 # of Instillations, around 3,000,000 around 6,000,000 2012
Slide 60: NCI cancer research funding
NCI cancer research funding (106 USD) Cancer 2010 2011 2012 2013 Incidence 5 year type spending spending spending vs deaths survival Lung 282 297 315 228,190/159,480 16.6% Prostate 301 288 265 238,590/29,720 99.2% Breast 631 625 602 232,340/39,620 89.2% Colorectal 270 265 256 142,820/50,380 64.9% Bl
Slide 61: Conclusion 1: bladder cancer
Conclusion 1: bladder cancer - Is very prevalent and costly - Has limited awareness and funding - Is a large potential market
Slide 62: Let's focus on NMIBC
Let’s focus on NMIBC (non muscle invasive bladder cancer)
Slide 63: Bladder Cancer
Bladder Cancer 6 Radboudumc
Slide 64: The unmet needs in NMIBC: 1) The operation
The unmet needs in NMIBC 1) The operation
Slide 65: Guideline for the management of nonmuscle invasive bladder cancer
Guideline for the management of nonmuscle invasive bladder cancer (Stages Ta, T1, and Tis): 2007 update M. Craig Hall,* Sam S. Chang,† Guido Dalbagni, Raj Som Pruthi, John Derek Seigne,‡ Eila Curlee Skinner, J. Stuart Worf, Jr.§ and Paul F. Schellhammer From the American Urological Association Educa
Slide 66: Transurethral Resection (TUR)
Transurethral Resection (TUR)
Slide 67: The initial surgical resection (TUR) is not complete in up to 50% of cases
The initial surgical resection (TUR) is not complete in up to 50% of cases a very high “recurrence” rate Risk Size Recurrences Progression in 2 years Low 30% 30% <1% Intermediate 40-50% 50-60% <5% High 20-30% 70-80% 10-30%
Slide 68: The unmet needs in NMIBC: 2) Adjuvant Treatment
The unmet needs in NMIBC 2) Adjuvant Treatment
Slide 69: Guideline adjuvant therapy
Guideline adjuvant therapy Low risk: Single Postoperative Instillation (SPI): recurrence rates reduced by +50% (30% 15% at 2 year) Intermediate risk: chemo of BCG: recurrence rates reduced by <50% (50-60% 30-40%) High risk: BCG: recurrence rates reduced by <50% (70-80% 40-50%) Not really very effect
Slide 70: Radboudumc
Radboudume
Slide 71: Single Postoperative Instillation is done only in a minority of patients
. Single Postoperative Instillation (SPI): is done only in a minority of patients US, Burks et al, J Urol 2012 SPI: 27?50% ideal pts, 9-24% non ideal pts Reasons for no SPI: logistic factors (24%), doubt about benefit (20%), resection aspects (17%), pt factors (malignancy uncertain, other th/ planne
Slide 72: Clinical practice gaps
Clinical practice gaps (Witjes et al., BJUI 2013) There is significant non-adherence to EAU and AUA guideline recommendations for BCG use in intermediate-and high-risk NMIBC. 47% of 197 intermediate-risk patients received EAU or AUA guideline-recommended intravesical therapy Of 774 high-risk patient
Slide 73: Guideline adjuvant therapy
Guideline adjuvant therapy Low risk: SPI: recurrence rates reduced by +50% (30% 15% at 2 year) Intermediate risk: chemo of BCG: recurrence rates reduced by <50% (50-60% 30-40%) High risk: BCG: recurrence rates reduced by <50% (70-80% 40-50%) Not really very effective Guidelines not followed in many
Slide 74: Guideline adjuvant therapy
Guideline adjuvant therapy Low risk: SPI: recurrence rates reduced by +50% (30% 15% at 2 year) Intermediate risk: chemo of BCG: recurrence rates reduced by <50% (50-60% 30-40%) High risk: BCG: recurrence rates reduced by <50% (70-80% 40-50%) Not really very effective Guidelines not followed in many
Slide 75: Conclusion 2: treatment NMIBC
Conclusion 2: treatment NMIBC Results are not very good many recurrences Reasons are TUR is not a good operation (we cut into the tumor!) Guideline advise treatments are not very effective Guidelines are not followed well BCG shortage Therefore there is a Large Unmet Medical Need
Slide 76: New developments...
New developments... Radboudume
Slide 77: In years, no new treatments have been approved and marketed
In 40 years, no new treatments have been approved and marketed Year Intravesical Agent 1961 Thiotepa 1975 BCG 1975 Mitomycin C No drug has ever been approved for immediate instillation for non-invasive bladder cancer in the U.S. or EU
Slide 78: Apaziquone
Apaziquone Radboudume
Slide 79: Historical Overview
Historical Overview 1980s First synthesized by Eef Oostveen at the University of Amsterdam (1987) 1990s Preclinical and early clinical studies conducted by EORTC Phase 2 trials of IV administration in solid tumors failed to show significant antitumor activity: lack of clinical activity of IV drug du
Slide 80: Apaziquone: Mechanism of Action
Apaziquone: Mechanism of Action Inactive pro-drug activated in a hypoxic environment (bladder) Activated by DT-diaphorase (high levels in bladder cancer) Apaziquone is active in bladder cancer Molecular weight prevents absorption and short (minutes) half life time Apaziquone is safe for use in the b
Slide 81: In Vitro Data
In Vitro Data (vdHeijden et al. J Urol 2005) On an average Apaziquone is 26 times more effective (range 6 to 78 times) than MMC
Slide 82: In Vitro Apaziquone Data
In Vitro Apaziquone Data Mitomycin C (0 – 0.30 mMol) Survival Cell 0.1 0.000 0.150 0.300 Concentration nM Survival Cell 0.1 0.000 0.150 0.300 Apaziquone (0 – 0.03 mMol) T24 Survival Cell 0.1 0.000 0.015 0.030 Concentration nM 253J Survival Cell 0.1 0.000 0.015 0.030
Slide 83: Clinical Phase and Data
Clinical Phase 1 and 2 Data mg in 50 mL identified as best dose Disappearance of tumor in 69%! (marker lesion) 9/12 in phase 1 study, 31/46 in phase 2 study40/58 side effects as with other chemotherapeutic instillations 49.5% of responders still tumor free after 18 months Valrubicin: 5 of 39 CR’s af
Slide 84: Apaziquone Clinical Study Data
Apaziquone Clinical Study Data Marker lesion before apaziquone treatment Marker lesion scar after apaziquone treatment
Slide 85: Clinical Phase and Data
Clinical Phase 1 and 2 Data mg in 50 mL identified as best dose Disappearance of tumor in 69%! (marker lesion) 9/12 in phase 1 study, 31/46 in phase 2 study40/58 side effects as with other chemotherapeutic instillations 49.5% of responders still tumor free after 18 months Valrubicin: 5 of 39 CR’s af
Slide 86: Marker lesion experiments in bladder cancer – what have we learned?
Marker lesion experiments in bladder cancer – what have we learned?
Slide 87: Apaziquone Phase 3 Clinical Trials (611 and 612)
Apaziquone Phase 3 Clinical Trials (611 and 612) Two double-blind, placebo-controlled, randomized Phase III clinical studies, initiated in 2007 Patients with primary or recurrent Ta, G1-G2 NMIBC 562 evaluable patients per trial Central Pathology read as Ta, G1-G2 Primary endpoint: Recurrence rate at
Slide 88: Apaziquone Phase 3 Patient Disposition
Apaziquone Phase 3 Patient Disposition SPI 611 SPI 612 N=802 N=813 Apaziquone Placebo Apaziquone Placebo (N=406)(N=396)(N=402)(N=410) N (%) N (%) N (%) N (%) Time to Instillation from TURBT (min) <=30 183(45.1) 199 (50.3) 138(34.3) 125(30.5) – 90 82 (20.2) 59 (14.9) 76 (18.9) 76 (18.5) – 120 32(7.9)
Slide 89: Apaziquone Phase 3 (ITT Population)
Apaziquone Phase 3 (ITT Population) Primary Endpoint – Recurrence at 2 years (ITT Population) SPI 611 SPI 612 N=802 N=812 Apaziquone Placebo Apaziquone Placebo (N=406)(N=396)(N=402)(N=410) Recurrence Rate 36.9% 42.2% 40.0% 46.1% 95% CI 32.2, 41.8 37.3, 47.2 35.2, 45.0 41.2, 51.1 Chi –square p-value
Slide 90: But, blood inactivates Apaziquone
But, blood inactivates Apaziquone O’Brien
Slide 91: Apaziquone Phase 3 Subgroup Analysis
Apaziquone Phase 3 Subgroup Analysis Primary Endpoint – Recurrence at 2 yrs (ITT Population): time to instillation 30–90 min SPI 611 SPI 612 N=141 N=152 Apaziquone Placebo Apaziquone Placebo (N=82)(N=59)(N=76)(N=76) Recurrence Rate 24.4% 40.7% 32.9% 51.3% 95% CI 15.6, 35.1 28.1, 54.3 22.5, 44.6 39.6
Slide 92: Apaziquone Phase 3 Combined Analysis
Apaziquone Phase 3 Combined Analysis 611 and 612 Apaziquone Placebo Apaziquone Placebo (N=577)(N=569)(N=117)(N=100) All 30 – 90 min Recurrence rate 38.8% 45.5% 28.2% 50.0% 95% CI 34.8, 42.9 41.4, 49.7 20.3, 37.3 39.8, 60.2 Chi-square test p=0.022 p=0.001 Difference in RR 6.7% 21.8% 95% CI 1.0, 12.4
Slide 93: Conclusion: Non invasive bladder cancer and Apaziquone
Conclusion: Non invasive bladder cancer and Apaziquone We need something new in NMIBCa Apaziquone’s Mechanism of Action confers advantages for intravesical use Apaziquone in vitro is very effective Apaziquone in vivo is safe with very promising efficacy
Slide 94: Poziotinib
Spectrum Pharmaceuticals Analyst Day 2015 Poziotinib
Slide 95: Francisco Esteva
Francisco Esteva MD, PhD Associate Director of Clinical Investigation Director, Breast Medical Oncology Program Laura and Isaac Perlmutter Cancer Center New York University, Langone, New York, NY
Slide 96: HER2-Targeted Therapies
HER2-Targeted Therapies mAbs Sovtines Penucama® : Tyrosine-kinase inhibitors Afatinib Erlotinib Gefitinib Lapatinib Neratinib Poziotinib
Slide 97: Chemotherapy Plus Trastuzumab in Metastatic Disease
Chemotherapy Plus Trastuzumab in Metastatic Disease Slamon et al Marty et al n = 469 n = 186 Treatment Arms AC or T* Docetaxel vs vs AC or T?H† Docetaxel ?H† Time to Disease P value P value Progression (mos) 4.6 7.4 < 0.001 6.1 11.7 0.0001 Response Rate 32% 50% < 0.001 34% 61% 0.0002 Median Overall
Slide 98: CLEOPATRA: First-Line Pertuzumab for MBC
CLEOPATRA: First-Line Pertuzumab for MBC R A N D HER2+ MBC O (N = 800) M I Z A T 90% of enrolled I patients O trastuzumab N naïve Baselga J, et al. N Engl J Med. 2012;366(2):109-119. Swain S, et al. Lancet Oncol. 2013;14(6):461-471. .
Slide 99: CLEOPATRA Overall Survival
Docetaxel 75 mg/m2* q3wk + Trastuzumab 8 mg/kg, ? 6 mg/kg q3wk + PLACEBO Docetaxel 75 mg/m2 q3wk +Trastuzumab 8 mg/kg, ? 6 mg/kg q3wk + Pertuzumab 840 mg cycle 1, 420 mg q3wk Primary endpoint: PFS *Docetaxel can be increased to 100 mg/m2 q3wk if tolerable. CLEOPATRA: First-Line Pertuzumab for HER2+
Slide 100: EMILIA: Second Line Trastuzumab-DM1
EMILIA: Second Line Trastuzumab-DM1 HER2-positive LABC T-DM1 or MBC (N=980) 3.6 mg/kg q3w IV PD Prior taxane and 1:1 trastuzumab Progression on Capecitabine metastatic treatment 1000 mg/m2 PO bid, days 1–14, q3w or within 6 months of + PD adjuvant treatment Lapatinib 1250 mg/day PO qd Stratification
Slide 101: EMILIA Overall Survival
EMILIA: Second Line Trastuzumab-DM1 HER2+ LABC Metastatic Breast Cancer—Overall Survival Median (months) No. of events Cap + Lap 25.1 182 1.0 T-DM1 30.9 149 85.2% Stratified HR=0.682 (95% CI, 0.55, 0.85); P=0.0006 Efficacy stopping boundary P=0.0037 or HR=0.727 0.8 78.4% 64.7% surviving 0.6 51.8% Pr
Slide 102: Phase III Study of Total HER2+ Blockade
Phase III Study to Test if Total HER2+ Blockade Improves Clinical Outcome Key Inclusion HER2+(FISH+/ IHC3+) MBC Progression on Anthracycline Taxane Trastuzumab Progression trastuzumab on regimen most recent Stratification Factors Visceral Disease Hormone Receptor R A N Lapatinib 1500 mg/day PO D N=1
Slide 103: Total HER2+ Blockade Overall Survival in ITT Population
Phase III Study to Test if Total HER2+ Blockade Improves Clinical Outcome for HER2+ Metastatic Breast Cancer -Overall Survival in ITT Population L L+T 100 N = 145 N = 146 Died, n 69 56 80% Median, wks 39.0 51.6 Hazard ratio (95% CI) 0.75 (0.53, 1.07) Surviving P value 0.106 70% 6Mo OS 45% Percentage
Slide 104: Improvements in Overall Survival Rates in HER2+ Metastatic Breast Cancer
Improvements in Overall Survival Rates in HER2+ Metastatic Breast Cancer First-line setting Second-line setting Third-/fourth-line (CLEOPATRA n=808)(EMILIA n=991)(EGF104900 n=291) Trastuzumab+ Trastuz Lapatinib+ Lapatinib pertuzumab+ + docetaxel capecitabine Lapatinib+ docetaxel T-DM1 trastuzumab Me
Slide 105: ExteNET Trial: Neratinib Extended Adjuvant Breast Cancer
ExteNET Trial: Neratinib HER2 Positive Extended Adjuvant Breast Cancer Early HER2+ Breast Cancer after trastuzumab R A N D O M I Z A T I O N Neratinib daily (1 year) Placebo (1 year) Primary endpoint: Invasive Disease Free Survival (IDFS) Positive Study Results announced July, 2014 clinicaltrials.go
Slide 106: Poziotinib: Orally active, irreversible pan-HER inhibitor
Poziotinib: Orally active, irreversible pan-HER inhibitor Active against HER-1 (EGFR), HER-2, HER-4, and receptor mutations including EGFR T790M
Slide 107: In-vitro Studies Show Poziotinib Activity Superior to Other HER TKIs
In-vitro Studies Show Poziotinib Activity Superior to Other HER Tyrosine Kinase Inhibitors In HER-2 breast cancer cells, Poziotinib showed superior in vitro activities than Neratinib and Afatinib In vitro activities of pan-HER TKIs in HER-2 breast cancer cells. SK-Br-3 MDA-MB-175 MDA-MB-453 Compound
Slide 108: Overview of Poziotinib Clinical Phase Trials
Overview of Poziotinib Clinical Phase 1 Trials Compounds Study PHI-101 Study PHI-102 Target population Advanced solid tumors Advanced solid tumors Regimen Monotherapy Monotherapy Dose escalation 0.5-32 mg Dose escalation 12-24 mg Dosing Expansion 24 mg Food effect 16 mg Schedule 2 weeks on, 1 week o
Slide 109: Poziotinib Phase Study Adverse Events Overview
Poziotinib Phase 1 Study Adverse Events Overview HM-PHI-101 No Grade 4 or 5 adverse events observed
Slide 110: Poziotinib Phase Study Tumor Response
Poziotinib Phase 1 Study Tumor Response Substantial tumor size reductions in heavily pre-treated patient with diverse tumors (NSCLC/breast/gastric cancers)
Slide 111: Poziotinib Phase Study Duration of Treatment
Poziotinib Phase 1 Study Duration of Treatment More than 40% of heavily pre-treated patients received ? 3 months of treatment and 5 patients were treated more than 1 year
Slide 112: Poziotinib Clinical Data in Breast Cancer Patients Failing Other HER TKIs
Poziotinib Clinical Data in Breast Cancer Patients Failing Other HER TKIs—Reason to be Optimistic… Molecule Company ORR No. of Prior HER2 Study HER2+ directed Patients therapy Lapatinib GlaxoSmithKline 6% 140 Trastuzumab Phase 2: (Tykerb®)(Approved 2007) Burstein et al. Neratinib Puma 24% 63 Trastuz
Slide 113: Poziotinib Phase 1: Breast Cancer
For illustrative purposes only. Comparisons across studies with different trial designs and parameters are not indicative of superiority or inferiority of any compound. Phase 1 Poziotinib: Breast Cancer Previous Initial Best Overall Study Lines of Prior HER-2 Directed Therapies Dose Response Therapy
Slide 114: Phase Poziotinib Clinical Studies
Phase 2 Poziotinib Clinical Studies NCT Number Status Population Sponsor/Collaborators Start Date Phases Lung Cancer- First-line therapy for National OncoVenture NCT01819428 Recruiting NSCLC with EGFR Activating March 2013 Phase 2 Hanmi Pharmaceutical Mutation Company Limited National OncoVenture Ac
Slide 115: Poziotinib Summary
Poziotinib Summary Orally active, irreversible pan-HER inhibitor with best in class potential Active against HER-1 (EGFR), HER-2, HER-4, and receptor mutations including EGFR T790M Effective and well tolerated in Phase 1 and 2 studies – Over 160 Patients treated to date Promising clinical activity i
Slide 116: Commercial Overview
Commercial Overview Tom Riga Senior Vice President and Chief Commercial Officer
Slide 117: Commercial Perspective
Commercial Perspective
Slide 118: Positioned For Long-Term Growth
Positioned For Long-Term Growth STRONG LONG-TERM GROWTH DRIVERS LATE-STAGE ASSETS WITH GROWTH POTENTIAL MULTIPLE ASSETS FUND PIPELINE Early Stage assets CE Melphalan Apaziquone Poziotinib SPI-2012 Business Development and Lifecycle Management See Package inserts for full indications and for details
Slide 119: Strong Commercial Performance in 2014
See Package Inserts for full indications and for details including safety information Strong Commercial Performance in 2014 2014 Total Sales ($MM) $40.1 Q1 Q2 Q3 Q4
Slide 120: Experienced Team
Experienced TEAM over 320 nationally recognized sales and marketing awards AVERAGE SPECTRUM COMMERCIAL TEAM EXPERIENCE Pharmaceutical Sales / Marketing 17 years Oncology Sales / Marketing 10 years
Slide 121: SPI-2012 Overview
SPI-2012 Overview Novel long acting biologic for chemotherapy induced neutropenia Pegfilgrastim Source of Business (US) Comparable efficacy in Phase 2 study Clinics [VALUE] Comparable adverse event profile with low immunogenicity in Phase 2 Study [VALUE] Hospitals $6 Billion worldwide market Source:
Slide 122: Capitalizing on Our Potential Blockbuster
Capitalizing on Our Potential Blockbuster TRUSTED PARTNERSHIPS
Slide 123: Poziotinib Overview
Poziotinib Overview 175,000+ total patients/year Irreversible pan-EGFR / HER inhibitor Gastric Cancer with Potential best in class HER2 expression 2,000 patients Breast Cancer with HER2 expression Potential use in breast, NSC lung, 60,000 patients and gastric cancer 175,000+ potential patients NSC L
Slide 124: Poziotinib—Reason to be Optimistic
Poziotinib—Reason to be Optimistic… Molecule Company ORR No. of Prior HER2 Study HER2+ directed Patients therapy Poziotinib Spectrum 60% 10 Trastuzumab Hanmi Aggregate Pharma/ Lapatinib Phase 1 Hanmi Pharma Pertuzumab* Neratinib Puma 24% 63 Trastuzumab Phase 2: Biotechnology Burstein et al. Lapatini
Slide 125: Poziotinib Phase 1: Breast Cancer
For illustrative purposes only. Comparisons across studies with different trial designs and parameters are not indicative of superiority or inferiority of any compound. Phase 1 Poziotinib: Breast Cancer Previous Lines Best Overall Study Initial Dose Prior HER-2 Directed Therapies of Therapy Response
Slide 126: Apaziquone Overview
Apaziquone Overview Next generation bioreductive alkylating agent being investigated for NMIBC treatment No new treatments Market opportunity of 52,000 new NMIBC patients annually approved in almost 40 years Robust activity with no systemic toxicity Thiotepa BCG Mitomycin C Today 1960 1970 1980 1990
Slide 127: Captisol-enabled Melphalan Overview
Captisol-enabled™ Melphalan Overview Two indications: Stem cell transplant High overlap with conditioning and palliative treatment in MM 136 existing MARQIBO target transplant centers ~$100 Million IV melphalan market CE-Melphalan target transplant centers Propylene glycol free Improved stability pr
Slide 128: Positioned Well for Long-Term Growth
Positioned Well for Long-Term Growth Experienced team that is executing today Two near?term NDA’s Game changing pipeline with two potential blockbuster drugs
Slide 129: Summary
Summary Rajesh Shrotriya Chairman and CEO
Slide 130: Analyst Day Summary
Analyst Day Summary Two Near-Term NDAs and Two Potential Blockbusters SPI-2012 is a novel biologic with blockbuster potential to mitigate neutropeniaPoziotinib has strong early data, validated MOA, targets large indicationsCE Melphalan is propylene glycol-free with an improved stability profile for
Slide 131: Q&A
Spectrum Pharmaceuticals Analyst Day 2015 Q&A
Slide 132: Spectrum Pharmaceuticals Analyst Day 2015
Spectrum Pharmaceuticals Analyst Day 2015